After receiving standard full-course anti-TB therapy combined anti-tumor therapy with chemotherapy, vascular targeting, and PD-1 inhibitor, the patient achieved ideal efficacy with mild adverse reactions, which is worthy of clinical reference. The gene discussed is PDCD1; the disease is tuberculosis.